Consolidated Planning Corp Has $4.36 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Consolidated Planning Corp raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 2.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,773 shares of the medical equipment provider’s stock after acquiring an additional 1,018 shares during the quarter. Consolidated Planning Corp’s holdings in Boston Scientific were worth $4,356,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Creative Planning lifted its position in Boston Scientific by 7.7% during the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock worth $17,113,000 after buying an additional 14,663 shares in the last quarter. NBC Securities Inc. increased its position in shares of Boston Scientific by 20.5% in the third quarter. NBC Securities Inc. now owns 11,761 shares of the medical equipment provider’s stock valued at $985,000 after acquiring an additional 2,001 shares during the last quarter. Swedbank AB raised its holdings in Boston Scientific by 0.6% during the third quarter. Swedbank AB now owns 1,430,925 shares of the medical equipment provider’s stock worth $119,912,000 after acquiring an additional 8,246 shares in the last quarter. Wolff Wiese Magana LLC boosted its position in Boston Scientific by 7,262.5% during the third quarter. Wolff Wiese Magana LLC now owns 2,945 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 2,905 shares during the last quarter. Finally, AAFMAA Wealth Management & Trust LLC grew its stake in Boston Scientific by 10.4% in the third quarter. AAFMAA Wealth Management & Trust LLC now owns 32,732 shares of the medical equipment provider’s stock valued at $2,743,000 after purchasing an additional 3,077 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Mizuho upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Wells Fargo & Company upped their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Raymond James lifted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 6th. Barclays boosted their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $107.39.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 12,000 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the sale, the director now owns 24,398 shares in the company, valued at $2,573,501.04. This represents a 32.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,830 shares of company stock worth $6,415,729 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.2 %

BSX opened at $105.80 on Thursday. The company’s 50 day moving average price is $95.50 and its two-hundred day moving average price is $87.72. The firm has a market capitalization of $155.93 billion, a price-to-earnings ratio of 84.64, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $64.54 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, research analysts predict that Boston Scientific Co. will post 2.83 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.